EFFORT: EFFicacy Of ceralasertib (AZD6738) and adavosertib (AZD1775) in parp ResisTance; A Randomized 3-arm non-comparative Phase 2 Study of adavosertib alone, adavosertib plus olaparib, and ceralasertib plus olaparib in Women with Ovarian Cancer who have progressed during PARP inhibition